About Dexon Biotech
Dexon Biotech is a company based in Ambala (India) founded in 2016. It operates as a B2B. Dexon Biotech offers products and services including Tablets, Capsules, and Injectables. Dexon Biotech operates in a competitive market with competitors including Unither, Akums, Jubilant Life Sciences, Recipharm and CoreRx, among others.
- Headquarter Ambala, India
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website dexonbiotech.com
- Social LinkedIn X Facebook Instagram
- Legal Name Dexon Biotech Private Limited
- Date of Incorporation 02 Nov, 2016
- Jurisdiction Ambala Cantt, Haryana, India
- Annual Revenue₹1.87 Cr
FY 2025 · +96% YoY
- Net Profit₹1.7 Lakh
FY 2025 · 1% margin
- EBITDA₹4.1 Lakh
FY 2025 · 2% margin
Associated legal entities of Dexon Biotech
Dexon Biotech operates through Dexon Biotech Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Dexon Biotech Private Limited CIN U24110HR2016PTC066268 | Active | 02 Nov 2016 | Ambala Cantt, Haryana | ₹1.9 Cr | – | 2 | View details |
Products & Services of Dexon Biotech
Dexon Biotech offers a comprehensive portfolio of products and services, including Tablets, Capsules, and Injectables.
Medicinal tablets for various health conditions
Encapsulated medicines for treatment purposes
Injectable drugs for medical administration
Board of directors of Dexon Biotech Private Limited (Dexon Biotech)
Dexon Biotech Private Limited is the primary company behind Dexon Biotech. The board of Dexon Biotech Private Limited currently have 2 directors; the longest-serving is Anmol Garg, appointed in 2021. 5 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Anmol Garg DIN 09100692 | Director | 10 Mar 2021 | 5 yrs 7 mo | Dexon Biotech Private Limited |
| Vivek Garg DIN 03471951 | Director | 29 Nov 2021 | 4 yrs 10 mo | Dexon Biotech Private Limited |
Financials of Dexon Biotech
Figures of Dexon Biotech Private Limited, the primary company behind Dexon Biotech, for FY 2025. Revenue was ₹1.87 Cr (+96% year on year). Net profit was ₹1.7 Lakh (1% margin). EBITDA was ₹4.1 Lakh (2% margin). Revenue has grown at a compounded annual rate of +59% over three years and +44% over five years.
- ₹1.87 CrRevenue · FY 2025 · +96% YoY
- ₹1.7 LakhNet profit · 1% margin
- ₹4.1 LakhEBITDA · 2% margin
- ₹1 LakhPaid-up capital
- +59%Revenue CAGR, 3 years
- +44%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Dexon Biotech Private Limited are on its company page.
Detailed financial statements for Dexon Biotech
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Competitors of Dexon Biotech
Dexon Biotech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Unither, Akums, Jubilant Life Sciences, Recipharm and CoreRx, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| unither-pharma.com | 1993 | Paris, France | – | – | Contract development and manufacturing organization for proprietary and generic drugs | |
| akums.in | 2004 | Delhi, India | $70M | 395 | CDMO focusing on spectrum of dosage forms and therapeutic segments | |
| jubl.com | 1978 | Noida, India | – | – | Company offering a suite of R&D and manufacturing services for small molecules and generics | |
| recipharm.com | 1995 | Jordbro, Sweden | – | 1,083 | Pharmaceutical development and manufacturing services are offered contractually. | |
| corerxpharma.com | 2006 | Clearwater, United States | $15M | – | CDMO with a focus on early phase drug product development | |
| neclife.com | 1995 | Chandigarh, India | $46.85M | 175 | Cephalosporin APIs and generic formulations are manufactured. | |
| windlas.com | 2001 | Gurugram, India | $12.96M | 1,264 | Biopharma regulatory affairs, quality control, and strategy services are provided. | |
| medpharm.com | 1998 | Guildford, United Kingdom | – | 108 | Topical and inhaled drug delivery formulations are developed and manufactured. |
Detailed competitors of Dexon Biotech
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Dexon Biotech
The website of Dexon Biotech (dexonbiotech.com) receives about 1.8K visits a month.
- Monthly visits1.8K
▲ 7.5% vs previous month
Similar companies to Dexon Biotech
10 companies that operate in the same segment as Dexon Biotech (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Dexon Biotech
Dexon Biotech was founded in 2016.
Dexon Biotech is headquartered in Ambala, India. It is registered at Ambala, Haryana, India.
The primary company behind Dexon Biotech, Dexon Biotech Private Limited, reported revenue of ₹1.87 Cr for FY 2025, up 96% year on year.
Dexon Biotech Pvt. Ltd. is a pharmaceutical company based in Ambala Cantt, Haryana, India, producing over 150 products including tablets, capsules, injectables, and Ayurvedic items. It operates through a franchise model for marketing and distribution across the domestic market, ensuring compliance with GMP and ISO standards. The company focuses on general to specialty drugs, serving wholesalers and partners with a wide product range.
Dexon Biotech's top competitors include Jubilant Life Sciences, Akums and Nectar Lifesciences.
Dexon Biotech offers Tablets, Capsules, and Injectables.
Dexon Biotech operates through Dexon Biotech Private Limited.
The legal entities of Dexon Biotech currently have 2 directors, including Anmol Garg, Vivek Garg.